Comparing PFE's and BMY's Immunology Drugs - Market Realist

Comparing PFE's and BMY's Immunology Drugs  Market Realist

Pfizer's (PFE) commercialized JAK (Janus kinase) inhibitor, Xeljanz, is approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.



Comments

Popular posts from this blog

Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC - Cancer Network